Phone: +61 3 8648 4530
Email us:

Immuron Ltd is a publicly listed Australian biopharmaceutical company (ASX: IMC) focused on oral immunotherapy using dairy-derived polyclonal antibody products for humans.  Immuron is a uniquely positioned biotechnology company in view of its versatile technology platform, comprising dairy derived polyclonal antibodies, capable of generating a wide range of products with a high safety profile.  This high safety profile makes it possible to complete pre-clinical studies relatively quickly and raises the prospect that the clinical development of Immuron’s products will be expedited.


Latest Announcements